CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-2.45%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.72B
AUM Growth
+$1.72B
(-24%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-13.93%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
67
New
8
Increased
11
Reduced
11
Closed
17
Top Buys
| 1 |
RAPP
Rapport Therapeutics
RAPP
|
$68.4M |
| 2 |
Axsome Therapeutics
AXSM
|
$32.2M |
| 3 |
Vaxcyte
PCVX
|
$31.3M |
| 4 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$28.6M |
| 5 |
UroGen Pharma
URGN
|
$27.7M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$107M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$44.6M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
$42.2M |
| 4 |
ALX Oncology
ALXO
|
$35M |
| 5 |
BridgeBio Pharma
BBIO
|
$34.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cullinan Oncology
CGEM
$456M
| $19.6M | 1.13% |
+1,125,000
| New | +$19.6M |
|
27
Rhythm Pharmaceuticals
RYTM
$6.75B
| $19.5M | 1.13% |
475,000
-75,000
| -14% | -$3.08M |
|
|
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
| $19.4M | 1.12% |
1,182,563
| – | – |
|
29
Y-mAbs Therapeutics
YMAB
$390M
| $17.5M | 1.01% |
+1,450,000
| New | +$17.5M |
|
30
Avidity Biosciences
RNA
$6.12B
| $17.4M | 1% |
+425,000
| New | +$17.4M |
|
31
Biomea Fusion
BMEA
$114M
| $16.1M | 0.93% |
3,570,872
| – | – |
|
|
CNTA
32
Centessa Pharmaceuticals
CNTA
$2.13B
| $14.6M | 0.84% |
1,611,600
+1,050,000
| +187% | +$9.48M |
|
|
33
Tarsus Pharmaceuticals
TARS
$2.44B
| $13.6M | 0.79% |
500,000
-1,639,102
| -77% | -$44.6M |
|
|
SLN
34
Silence Therapeutics
SLN
$237M
| $11.9M | 0.69% |
625,000
| – | – |
|
35
ArriVent BioPharma
AVBP
$781M
| $9.55M | 0.55% |
515,000
| – | – |
|
36
enGene Holdings
ENGN
$249M
| $9.43M | 0.54% |
1,000,000
| – | – |
|
37
Korro Bio
KRRO
$244M
| $9M | 0.52% |
265,826
-263,344
| -50% | -$8.92M |
|
38
IDEAYA Biosciences
IDYA
$2.26B
| $8.6M | 0.5% |
245,000
-205,000
| -46% | -$7.2M |
|
39
GH Research
GHRS
$870M
| $6.91M | 0.4% |
593,043
| – | – |
|
40
Lantheus
LNTH
$3.75B
| $6.02M | 0.35% |
75,000
| – | – |
|
41
Stoke Therapeutics
STOK
$1.08B
| $5.77M | 0.33% |
427,163
| – | – |
|
42
Mersana Therapeutics
MRSN
$34.8M
| $5.23M | 0.3% |
104,000
| – | – |
|
43
Neurogene
NGNE
$284M
| $3.91M | 0.23% |
107,344
-431,370
| -80% | -$15.7M |
|
44
VYNE Therapeutics
VYNE
$8.09M
| $2.75M | 0.16% |
1,394,336
| – | – |
|
45
Compass Therapeutics
CMPX
$466M
| $2.03M | 0.12% |
2,030,823
-3,529,477
| -63% | -$3.53M |
|
|
VERV
46
DELISTED
Verve Therapeutics
VERV
| $1.71M | 0.1% |
350,000
| – | – |
|
47
RAPT Therapeutics
RAPT
$187M
| $1.52M | 0.09% |
62,094
| – | – |
|
|
48
ALX Oncology
ALXO
$54.6M
| – | – |
-3,142,079
| Closed | -$35M |
|
49
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-400,000
| Closed | -$23.5M |
|
50
Astria Therapeutics
ATXS
$372M
| – | – |
-1,300,000
| Closed | -$18.3M |
|